Share Email Print
cover

Proceedings Paper

Meta-tetrahydroxyphenylchlorin (mTHPC) mediated photodynamic therapy: experience and thoughts after 17 treatments
Author(s): Mike G. Dilkes; Martin L. DeJode
Format Member Price Non-Member Price
PDF $14.40 $18.00

Paper Abstract

Over the past 14 months we have treated a wide variety of head and neck cancer patients with mTHPC mediated photodynamic therapy. This drug is a very powerful second generation photosensitizer with significant advantages over earlier drugs. Patients treated range from palliative to primary (curative) to adjunctive (intraoperative) cases. Following promising results we are now setting up a multicenter European study to treat early head and neck cancer with this drug/light combination, along with other collaborative studies to look further at the role of adjunctive PDT.

Paper Details

Date Published: 1 March 1995
PDF: 6 pages
Proc. SPIE 2371, 5th International Photodynamic Association Biennial Meeting, (1 March 1995); doi: 10.1117/12.203353
Show Author Affiliations
Mike G. Dilkes, The Royal London Hospital (United Kingdom)
Martin L. DeJode, The Royal London Hospital (United Kingdom)


Published in SPIE Proceedings Vol. 2371:
5th International Photodynamic Association Biennial Meeting
Denis A. Cortese, Editor(s)

© SPIE. Terms of Use
Back to Top